GlassScriptPhysician profile
Eliezer Parnes
NPI 1578564274
$4,676.34
in general payments reported to CMS, 2019-2025
26 companies · $977 in 2025
The $977 reported for 2025 was more than what 77% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $409 · 2020: $299 · 2021: $343 · 2022: $758 · 2023: $816 · 2024: $1,075 · 2025: $977.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,762 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,761.96 |
| Education | $106.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $749.43 | 2019-2025 | Farxiga, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $601.63 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $564.41 | 2021-2025 | |
| Lilly USA, LLC | $405.65 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $370.85 | 2019-2025 | Jynarque |
| Opko Pharmaceuticals, LLC | $262.64 | 2019-2025 | Rayaldee |
| Mallinckrodt Hospital Products INC. | $245.65 | 2022-2025 | Acthar |
| Vifor Pharma, INC. | $211.62 | 2019-2024 | Veltassa, Korsuva |
| Novo Nordisk INC | $152.85 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $148.53 | 2021-2022 | |
| Amgen INC. | $119.16 | 2019-2025 | Krystexxa, Parsabiv, Aranesp |
| Pfizer INC. | $118.07 | 2019-2025 | |
| Akebia Therapeutics INC | $104.80 | 2019-2025 | Vafseo |
| Horizon Therapeutics Plc | $104.52 | 2022-2023 | Krystexxa |
| Ardelyx, INC. | $87.49 | 2024-2025 | Ibsrela |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $83.05 | 2023 | Purified Cortrophin Gel |
| Daiichi Sankyo INC. | $69.08 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $66.65 | 2019 | |
| Novartis Pharmaceuticals Corporation | $50.12 | 2024-2025 | |
| Amarin Pharma, INC. | $44.33 | 2020-2022 | |
| Kyowa Kirin, INC. | $24.98 | 2025 | |
| Esperion Therapeutics, INC. | $21.34 | 2024 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $21.07 | 2023 | Eliquis |
| Cormedix INC. | $20.64 | 2025 | Defencath |
| Actelion Pharmaceuticals US, INC. | $14.61 | 2022 | |
| Travere Therapeutics, INC. | $13.17 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eliezer Parnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.